



UNIVERSIDADE FEDERAL DE SERGIPE
PRÓ-REITORIA DE GRADUAÇÃO
DEPARTAMENTO DE ODONTOLOGIA

Jéssika Ingrid Gomes Malta

AVALIAÇÃO DA DENSIDADE ÓPTICA DO CIMENTO PORTLAND
ASSOCIADO A AGENTES RADIOPAIFICADORES EM DIFERENTES
PROPORÇÕES

ARACAJU- SE

2015

JÉSSIKA INGRID GOMES MALTA

**AVALIAÇÃO DA DENSIDADE ÓPTICA DO CIMENTO PORTLAND
ASSOCIADO A AGENTES RADIOPACIFICADORES EM DIFERENTES
PROPORÇÕES**

Trabalho de conclusão de curso apresentado a
Universidade Federal de Sergipe como pré-
requisito para obtenção do título de Cirurgiã-
dentista

Orientador: Prof. Dr. Wilton Mitsunari
Takeshita

ARACAJU- SE

2015

AGRADECIMENTOS

Agradeço inicialmente a Deus por todas as oportunidades que me foram permitidas.

À minha família pela paciência em tolerar a ausência durante alguns momentos e pelo apoio que sempre me deram para seguir em frente. Vocês são os responsáveis por essa vitória. Muito obrigada!

Aos meus amigos e familiares pela eterna torcida.

À Universidade Federal de Sergipe e ao Departamento de Odontologia por me apresentar à odontologia, profissão hoje que tenho orgulho de fazer parte e que tanto amo.

Ao programa de iniciação científica PIBIC, que, por duas vezes, me incentivou a entrar no universo das pesquisas científicas.

Ao meu orientador Prof. Wilton Takeshita Mitsunari pelo incentivo, prontidão no auxílio das atividades e pela extrema competência.

A todos os professores pelo carinho, dedicação e entusiasmo demonstrado ao longo do curso.

Aos colegas de classe por todos os anos de convivência e amizade.

RESUMO

AVALIAÇÃO DA DENSIDADE ÓPTICA DO CIMENTO PORTLAND ASSOCIADO A AGENTES RADIOPAIFICADORES EM DIFERENTES PROPORÇÕES

Jessika Ingrid Gomes Malta, Wilton Mitsunari Takeshita. Universidade Federal de Sergipe. 2015.

Objetivo: Avaliar o potencial radiopacificador de algumas substâncias associadas ao cimento Portland (CP) em diferentes concentrações quando comparados ao MTA. **Materiais e métodos:** Foram avaliados neste estudo o cimento Portland, o MTA e os seguintes radiopacificadores: iodofórmio, óxido de bismuto, óxido de chumbo, subnitrato de bismuto, sulfato de bário e óxido de zircônio. Prepararam-se as amostras de acordo com a determinação nº 57 (2000) da ANSI-ADA. Adicionou-se ao cimento Portland radiopacificadores referidos nas proporções de 15%, 20% e 30%. Cada amostra foi radiografada ao lado do *stepwedge*, utilizando um sensor de radiografia digital Instrumentarium Kavo EXPRESS®. O programa Adobe Photoshop®CS6 foi utilizado para a análise da radiopacidade dos cimentos e os dados foram submetidos à análise estatística ANOVA e teste Tukey a nível de significância de 5%. **Resultados:** O cimento Portland puro (CP) apresentou o menor valor de radiopacidade. O CP adicionado de radiopacificadores apresentou o maior valor de radiopacidade para o CP+Óxido de chumbo na proporção de 30% (4,7365 mmEq.Al) e o menor foi para o CP+sulfato de bário na proporção de 15% (1,5760 mmEq.Al). **Conclusão:** O cimento Portland apresentou densidade óptica mais próxima do MTA quando associado ao subnitrato de bismuto a 20% e iodofórmio a 20%. A adição de radiopacificadores a 15% não são ideais para melhorar a radiopacidade do cimento Portland.

Palavras-chave: cimentos dentários, agregado trióxido mineral, material reparador, cimento portland.

ABSTRACT

EVALUATION OF OPTICAL DENSITY ASSESSMENT OF PORTLAND CEMENT ASSOCIATED WITH AGENTS RADIOPACIFIERS IN DIFFERENT PROPORTIONS.

Jessika Ingrid Gomes Malta, Wilton Mitsunari Takeshita. Federal University of Sergipe. 2015.

Objective: Evaluate the radiopacifier potential of some substances associated with Portland cement (CP) at different concentrations when compared to MTA. **Methods:** Were evaluated in this study Portland cement, the MTA and the following radiopacifiers : iodoform , bismuth oxide , lead oxide , bismuth subnitrate , barium sulfate and zirconium oxide . Samples were prepared according to the determination No 57 (2000) ANSI -ADA. Was added to the Portland cement in the proportions of said radiopacifying 15 %, 20 % and 30 %. Each sample was imaged next to the stepwedge using a digital radiography sensor Instrumentarium Kavo EXPRESS®. Adobe Photoshop®CS6 program was used to analyze the radiopacity of the cement and the data were subjected to statistical analysis ANOVA and Tukey test at a significance level of 5 %. **Results:** The pure Portland cement (PC) had the lowest amount of radiopacity . The CP addition of radiopacifiers showed the highest amount of radiopacity for the CP + lead oxide in a proportion of 30 % (4,7365 mmEq.Al) and was lowest for the CP + barium sulfate in a ratio of 15 % (1,5760 mmEq.Al). **Conclusion :** The Portland cement showed nearest optical density of MTA when combined with bismuth subnitrate (20%) and iodoform (20%). The addition of radiopacifiers 15% are not ideal for enhancing the radiopacity of Portland cement.

Keywords: dental cements, mineral trioxide aggregate, root-end filling materials, portland cement.

SUMÁRIO

1 Introdução.....	7
2 Materiais e métodos.....	9
3 Resultados.....	11
4 Discussão.....	16
5 Referências.....	19
Anexo A – Regras de submissão.....	22

1. INTRODUÇÃO

A radiopacidade dos materiais odontológicos é de extrema importância para o diagnóstico radiográfico. Sendo assim aceita como uma propriedade necessária em todos os materiais odontológicos. Entre eles podemos citar os materiais protéticos, cimentos endodônticos, agentes cimentantes, resinas compostas diretas e indiretas, entre outros.^[1]

Desde que as primeiras pesquisas confirmaram as excelentes propriedades físicas e biológicas do agregado de trióxido mineral,^[2,3] também conhecido como MTA, o seu uso tem se difundido na Odontologia. O uso do MTA, com base em evidências científicas e em estudos clínicos, é dirigido para o tratamento de acidentes e complicações endodônticas.^[5,6] A biocompatibilidade^[7] e composição química^[8,9] do cimento Portland (CP) são semelhantes aos do MTA, exceto a presença da partícula radiopacificadora. O cimento Portland tem sido proposto como um material alternativo para reparação retrógrada do canal radicular,^[10,11] em substituição ao MTA, uma vez que suas propriedades físicas são semelhantes.^[11] A partir do momento em que se identificaram semelhanças na composição dessa substância e do cimento tipo Portland utilizado na construção civil^[12,14], inúmeras pesquisas laboratoriais e in vivo^[12,15] surgiram diante da possibilidade de estender os benefícios desse material, de custo significativamente menor, a uma parcela maior da população que necessita de tratamentos endodônticos complexos. No entanto, o cimento Portland é menos radiopaco do que o MTA,^[16] limitando sua visualização radiográfica após a inserção na cavidade radicular. Essa menor radiopacidade se deve à ausência do óxido de bismuto em sua composição, que é o responsável pela radiopacidade do MTA. A fim de resolver este problema, agentes radiopacificadores que são normalmente utilizados em materiais dentários, têm sido propostos para serem agregados ao cimento Portland.

A especificação da ISO (International Organization for Standardization) número 57 certifica que a radiopacidade mínima de um material endodôntico na espessura de 1 mm deve ser igual ou maior do que a de 3 mm de densidade de um *stepwedge* de alumínio (3mmEq.Al).^[17] O Conselho em Materiais Dentários e Aparelhos da American Dental Association (ADA), em concordância com a especificação nº57 publicada em 1983, sugeriram a inclusão da declaração de que a densidade óptica é um requisito necessário em todos os materiais endodônticos.^[17,19]

O MTA é composto, basicamente, por cimento Portland acrescido de um radiopacificador, em uma proporção de 4:1 respectivamente. No entanto, o cimento Portland tem um inconveniente, que é a sua baixa radiopacidade, quando utilizado em condições de uso clínico, o que dificulta sua visualização e impossibilita a distinção das estruturas anatômicas adjacentes, como dentina e osso, justificando o presente trabalho de pesquisa. O resultado é de importância clínica, pois interessa não só ao radiologista, mas, especialmente, ao clínico, que poderá distinguir os cimentos entre si, dos

outros materiais, das estruturas dentárias, de lesões de cárie e outras alterações.^[23] Sabendo-se que a radiopacidade obtida na análise clínico-radiográfica depende da natureza do agente radiopacificador e da proporção em que o mesmo é adicionado ao cimento, este estudo investigará o potencial radiopacificador de algumas substâncias adicionados ao cimento tipo Portland em diferentes concentrações.

O objetivo deste trabalho foi avaliar a densidade óptica do cimento Portland adicionado de agentes radiopacificadores em diferentes proporções, tendo o MTA como referência.

2. MATERIAIS E MÉTODOS

Os seguintes radiopacificadores foram avaliados neste estudo: iodofórmio (MAQUIRA, Maringa, Brazil), óxido de bismuto (TODINI, Monza, Italy), óxido de chumbo (SS WHITE, Rio de Janeiro, Brazil), subnitrato de bismuto (FARMAQUIMIA DO BRASIL IMPORTAÇÃO E EXPORTAÇÃO LTDA, São Paulo, Brazil), sulfato de bário (CRISTALIA, São Paulo, Brazil) e óxido de zircônio (NANUM, Minas Gerais, Brazil). Prepararam-se as amostras de acordo com a determinação nº 57 (2000) da ANSI-ADA. Mediante pesagem em balança de precisão (LANTESCALE, China), adicionou-se ao cimento Portland os diferentes radiopacificadores referidos nas proporções de 15%, 20% e 30%. Cada amostra representou uma proporção e teve sempre o MTA (ANGELUS, Londrina, Brazil), que foi utilizado na comparação, e o cimento Portland branco puro (VOTORANTIM, Sergipe, Brazil) como grupo controle. Para cada porcentagem foram confeccionadas três amostras, totalizando nove placas acrílicas.

Vaso 1	MTA	-
Vaso 2	Cimento Portland puro (10g)	-
Vaso 3	Cimento Portland (8,5g) + iodofórmio (1,5g)	15%
Vaso 4	Cimento Portland (8,0g) + iodofórmio (2,0g)	20%
Vaso 5	Cimento Portland (7,0g) + iodofórmio (3,0g)	30%
Vaso 6	Cimento Portland (8,5g) + óxido de chumbo (1,5g)	15%
Vaso 7	Cimento Portland (8,0g) + óxido de chumbo (2,0g)	20%
Vaso 8	Cimento Portland (7,0g) + óxido de chumbo (3,0g)	30%
Vaso 9	Cimento Portland (8,5g) + óxido de zircônio (1,5g)	15%
Vaso 10	Cimento Portland (8,0g) + óxido de zircônio (2,0g)	20%
Vaso 11	Cimento Portland (7,0g) + óxido de zircônio (3,0g)	30%
Vaso 12	Cimento Portland (8,5g) + subnitrato de bismuto (1,5g)	15%
Vaso 13	Cimento Portland (8,0g) + subnitrato de bismuto (2,0g)	20%
Vaso 14	Cimento Portland (7,0g) + subnitrato de bismuto (3,0g)	30%
Vaso 15	Cimento Portland (8,5g) + sulfato de bário (1,5g)	15%
Vaso 16	Cimento Portland (8,0g) + sulfato de bário	20%
Vaso 17	Cimento Portland (7,0g) + sulfato de bário (3,0g)	30%
Vaso 18	Cimento Portland (8,5g) + óxido de bismuto (1,5g)	15%
Vaso 19	Cimento Portland (8,0g) + óxido de bismuto (2,0g)	20%
Vaso 20	Cimento Portland (7,0g) + óxido de bismuto (3,0g)	30%

Figura 1. Tabela referente à disposição dos radiopacificadores e suas respectivas proporções.

O MTA, o cimento Portland puro (CP) e o CP com os radiopacificadores foram espatulados com água destilada e inseridos nos orifícios de placas acrílicas (10mm x 30mm) com espessura de 1 mm, contendo cavidades de 5mm de diâmetro seguindo uma sequência ordenada alfabeticamente, por meio de marcações feitas nas placas, de acordo com a primeira letra da marca comercial, utilizando-se uma espátula Thompson nº6 (Miltex, inc., Tuttlingen, Alemanha). O material foi pressionado por uma lâmina de vidro de 5 mm de espessura intermediada por uma lâmina plástica

para transparência (Maxprint) do mesmo tamanho, cujo objetivo é limitar a espessura do material a ser inserido e nivelar a superfície prevenindo a formação de bolhas, de acordo com Rizon. As placas foram protegidas por filme de PVC (Polivinil Carbono) visando prevenir contaminações.^[24]

Um *stepwedge* de alumínio (1100) de oito degraus foi utilizado para correlacionar a densidade das imagens das amostras às do alumínio, permitindo verificar concordância com os requerimentos da International Standard Organization (*Specification 57*) para materiais endodônticos (ISO 6876-2001).^[18]

Cada amostra foi radiografada ao lado do *stepwedge*, utilizando um sensor de placa de fósforo baseado em um sistema de radiografia digital semi-direto Instrumentarium Kavo EXPRESS® (Joinville, Brasil), por meio de um aparelho de raios X odontológico GNATUS® Timex 70 E (Ribeirão Preto, Brasil), utilizando um tempo de exposição de 0,32 segundos e uma distância foco-filme de 40 cm para cada placa.^[25,26]



Figura 2. Sensor, placa de fósforo e amostras posicionadas para exposição radiográfica.

O programa Adobe Photoshop® foi utilizado para a análise da radiopacidade dos cimentos. Todas as imagens foram capturadas com resolução fixa de 600 dpi (*dots per inch*) e arquivadas em formato *TIFF*. As imagens foram importadas para o programa Adobe Photoshop, sendo que a leitura da radiopacidade foi realizada em quatro diferentes áreas em cada amostra do cimento reparador, e no terceiro degrau equivalente a 3 mm do *stepwedge*, calculando-se os valores médios de densidade óptica.^[19]




Figura 3. Radiografias dos diferentes radiopacificadores em diferentes proporções (15%, 20% e 30% respectivamente).

3. RESULTADOS

De acordo com metodologia do presente trabalho de pesquisa foram obtidos os seguintes resultados apresentados na sequência.

Para a proporção de 15%, o MTA não diferiu estatisticamente do CP + óxido de chumbo, CP + óxido de zircônio e do CP + subnitrato de bismuto. No entanto, a radiopacidade desses materiais foi inferior à 3,0 mmAl [Quadro 2].

Para a proporção de 20%, o MTA não diferiu estatisticamente do CP + iodofórmio, CP + óxido de chumbo, CP + óxido de zircônio, CP + subnitrato de bismuto, CP + sulfato de bário e do CP + óxido de bismuto. Destes, o CP + óxido de zircônio e o CP + sulfato de bário apresentaram suas radiopacidades inferiores à do terceiro degrau [Quadro 4].

Na proporção de 30%, o MTA não diferiu estatisticamente do CP + iodofórmio, CP + óxido de zircônio, CP + subnitrato de bismuto e do CP + sulfato de bário. Apenas o CP + sulfato de bário possui a radiopacidade inferior à 3,0 mmAl [Quadro 6].

As densidades do CP + óxido de bismuto a 20% e do CP + subnitrato de bismuto a 30% são superiores ao quarto degrau do stepwedge de alumínio.

Os materiais que apresentaram melhor radiopacidade foram o CP + subnitrato de bismuto a 20% e o CP + iodofórmio a 20%, 3.0526 mmEqAl e 3.3704 mmEqAl respectivamente.

Quadro 1 – análise de variância (ANOVA) para a proporção de 15% de radiopacificador.

ANOVA

	Soma dos quadrados	Df	Média dos quadrados	F	Sig.
Between Groups	6,750	7	,964	11,550	,000
Within Groups	1,336	16	,083		
Total	8,085	23			

Quadro 2 – Estatística descritiva e teste Tukey para a proporção de 15% de radiopacificador.

	Média	Desvio padrão	Intervalo de confiança a 95%		Grupos homogêneos
			Limite inferior	Limite superior	
MTA	3,2095	,12645	2,8954	3,5236	A
Cimento Portland (CP)	1,5438	,19913	1,0492	2,0385	B
CP + Iodofórmio	2,3716	,32371	1,5675	3,1757	CD
CP + Óxido de chumbo	2,8493	,23630	2,2623	3,4363	AD
CP + Óxido de Zircônio	2,4298	,49467	1,2010	3,6586	AD
CP + Subnitrato de Bismuto	2,4246	,33070	1,6031	3,2461	AD
CP + Sulfato de Bário	1,5760	,20830	1,0585	2,0934	BC
CP + Óxido de Bismuto	2,3149	,23265	1,7370	2,8928	BCD

*Letras diferentes indicam diferença estatística significativa ($p < 0,05$)

Quadro 3 – análise de variância (ANOVA) para a proporção de 20% de radiopacificador.

ANOVA

	Soma dos quadrados	Df	Média dos quadrados	F	Sig.
Between Groups	9,938	7	1,420	9,745	,000
Within Groups	2,331	16	,146		
Total	12,268	23			

Quadro 4 – Estatística descritiva e teste Tukey para a proporção de 20% de radiopacificador.

	Média	Desvio padrão	Intervalo de confiança a 95%		Grupos homogêneos
			Limite inferior	Limite superior	
MTA	3,2095	,12645	2,8954	3,5236	ACD
Cimento Portland (CP)	2,1016	,03596	2,0123	2,1909	B
CP + Iodofórmio	3,3704	,36590	2,4614	4,2793	CD
CP + Óxido de chumbo	3,5756	,48766	2,3642	4,7870	CD
CP + Óxido de Zircônio	2,6806	,49041	1,4623	3,8988	ABC
CP + Subnitrato de Bismuto	3,0526	,02409	2,9927	3,1124	ABC
CP + Sulfato de Bário	2,2263	,06754	2,0585	2,3940	AB
CP + Óxido de Bismuto	4,1427	,72855	2,3329	5,9525	D

*Letras diferentes indicam diferença estatística significativa ($p < 0,05$)

Quadro 5 – análise de variância (ANOVA) para a proporção de 30% de radiopacificador.

	Soma dos quadrados	Df	Média dos quadrados	F	Sig.
Between Groups	20,871	7	2,982	24,284	,000
Within Groups	1,964	16	,123		
Total	22,835	23			

Quadro 6 – Estatística descritiva e teste Tukey para a proporção de 30% de radiopacificador.

	Média	Desvio padrão	Intervalo de confiança a 95%		Grupos homogêneos
			Limite inferior	Limite superior	
MTA	3,2095	,12645	2,8954	3,5236	AC
Cimento Portland (CP)	1,7561	,18658	1,2926	2,2196	B
CP + Iodofórmio	3,6788	,50176	2,4323	4,9252	CE
CP + Óxido de chumbo	4,7365	,49263	3,5127	5,9602	D
CP + Óxido de Zircônio	3,8003	,19526	3,3153	4,2854	CDE
CP + Subnitrato de Bismuto	3,9619	,10773	3,6943	4,2295	CDE
CP + Sulfato de Bário	2,5968	,33562	1,7631	3,4306	AB
CP + Óxido de Bismuto	4,5789	,52401	3,2772	5,8806	DE

*Letras diferentes indicam diferença estatística significativa ($p < 0,05$)

Para determinação do teste foi realizado a avaliação de normalidade, utilizando o teste Shapiro-Wilk, em seguida, foi realizado a análise de variância (ANOVA) e teste de Tukey ao nível de significância de 5%.

4. DISCUSSÃO

O agregado trióxido mineral (MTA) foi inicialmente desenvolvido para selar comunicações entre o dente e a superfície externa periodontal.^[2,3] Foram encontradas no MTA propriedades como a alta alcalinidade, baixa solubilidade, excelente selamento marginal, capacidade antimicrobiana, alta radiopacidade, estabilidade dimensional, resistência à compressão e elevada biocompatibilidade. Diante destas características, o MTA passou a ser credenciado como um material promissor para uso em procedimentos endodônticos reparadores.^[2,3,5]

Estudos em análise microbiológica e química, verificaram que o MTA possui composição química e propriedades físicas semelhantes ao cimento Portland (CP), porém este possui um custo bastante inferior. Holland et al^[15] verificaram, ainda, que os dois compostos possuem propriedades biológicas semelhantes, porém o cimento Portland tem um inconveniente, que é a sua baixa radiopacidade, o que dificulta sua visualização radiograficamente.^[11]

Até o final da década de 80, os estudos sobre radiopacidade de materiais reparadores foram predominantemente realizados empregando o método do fotodensitômetro para leitura de radiopacidade em películas radiográficas, de acordo com as recomendações da American Dental Association (ADA). Nesse método, a radiopacidade do cimento é comparada com uma escala de alumínio com degraus de diferentes espessuras, sendo feita a equivalência da radiopacidade em milímetros de alumínio.^[24]

Estudos mais recentes sobre radiopacidade de cimentos têm utilizado a radiografia digital ou imagens digitalizadas, pois este método radiográfico necessita menor tempo de exposição e elimina a etapa do processamento químico, responsável pelas variações na qualidade da imagem, além de permitir melhor observação da densidade e do contraste radiográfico. Atualmente existem inúmeros métodos de digitalização da imagem radiográfica. Antes, a capacidade de armazenar e mostrar imagens de boa qualidade era restrita a empresas do ramo, no entanto, hoje tornaram-se populares e de fácil acesso a população.^[24]

No presente estudo, as imagens radiográficas foram obtidas por meio de sensores radiográficos e analisadas através do programa Adobe Photoshop para a determinação das densidades radiográficas dos materiais testados em comparação com uma escala de alumínio. Raitz et al^[19] utilizaram o mesmo método de avaliação radiográfica em um estudo sobre a comparação entre a radiografia panorâmica convencional e digitalizada na análise de lesões ósseas periapicais.

Trindade et al^[32] sugeriram a adição de 30% de radiopacificadores ao agregado de trióxido mineral com o intuito de facilitar sua visualização radiográfica nos tratamentos em que a espessura do material não se apresentar suficiente para destacar sua presença. Conforme os resultados deste

trabalho, os únicos materiais que apresentam radiopacidade necessária para visualização quando estão à uma proporção de 30% são CP + iodofórmio, CP + óxido de zircônio, CP + subnitrato de bismuto.

Figueiredo et al ^[31] demonstraram que o cimento Portland tem densidade óptica bastante inferior ao cimento MTA. À medida que proporções crescentes de subnitrato de bismuto foram incorporados ao cimento Portland, houve um aumento dos valores em pixels o que se traduz em maior radiopacidade, sendo que a última amostra (33%) chega a ultrapassar os valores do MTA. Os resultados do presente trabalho corroboram com os de Figueiredo. Nas proporções de 15 e 20%, o CP + subnitrato de bismuto são estatisticamente semelhantes ao MTA, diferindo na proporção de 30%.

Tanomaru et al ^[30] compararam a radiopacidade do cimento Portland quando adicionado de diferentes radiopacificadores, dentre eles, o sulfato de bário, usado no presente trabalho. Segundo ele, o cimento Portland puro e associado ao sulfato de bário não atendem à norma número 57 da ADA, que determina radiopacidade mínima de 3 mm de alumínio. Este trabalho confirma os resultados que Tanomaru, já que em nenhuma das proporções testadas, o CP associado ao sulfato de bário obteve radiopacidade superior ao terceiro degrau de alumínio.

Segundo Bodanezi et al ^[28], o óxido de bismuto na concentração de 20% em peso, apresentou-se como um agente capaz de conferir níveis de radiopacidade estatisticamente equivalentes ao da guta-percha e, ao mesmo tempo, superiores aos das combinações de cimento Portland com subnitrato de bismuto ou sulfato de bário. Conforme os resultados deste trabalho, a adição desses agentes radiopacificadores ao cimento Portland, na concentração de 20%, se mostrou a mais viável.

Kim et al ^[33] avaliaram a radiopacidade do cimento Portland contendo diferentes proporções de óxido de bismuto. Os resultados revelaram que a proporção de 20% propiciou a melhor radiopacidade, estatisticamente significativa, quando comparado às outras proporções. Os resultados corroboram com o presente trabalho, já que somente a 20% ele não apresentou diferenças estatísticas em relação ao MTA.

Diante dos resultados deste estudo, a adição de agentes radiopacificadores ao cimento Portland se mostra viável nas concentrações de 20% e 30%. Contudo, antes que esses compostos possam ser recomendados ao uso clínico, novos ensaios são necessários para comprovar esses achados e verificar a interferência de maiores quantidades dessas substâncias radiopacificadoras nas propriedades físico, química e biológica dos cimentos reparadores.

5. REFERÊNCIAS

1. Bouschlicher MR, Cobb DS, Boyer DB. Radiopacity of compomers, flowable and conventional resin composites for posterior restorations. *Oper Dent*. 1999; 24(1):20-25.
2. Lee SJ, Monsef M, Torabinejad M. Sealing ability of a mineral trioxide aggregate for repair of lateral root perforations. *J Endod*. 1993; 19:541-4.
3. Torabinejad M, Chivian N. Clinical application of mineral trioxide aggregate. *J Endod*. 1999; 25:197-205.
4. Torabinejad M, Parirokh M. Mineral trioxide aggregate: A comprehensive literature review - Part II: Leakage and biocompatibility investigations. *J Endod*. 2010; 36:190-202.
5. Parirokh M, Torabinejad M. Mineral trioxide aggregate: A comprehensive literature review - Part III: Clinical applications, drawbacks, and mechanism of action. *J Endod*. 2010; 36:400-413.
6. Martínez Lalis R, Esain ML, Kokubu GA, Willis J, Chaves C, Grana DR. Rat subcutaneous tissue response to modified Portland cement, a new mineral trioxide aggregate. *Braz Dent J* 2009; 20:112-117.
7. Oliveira MG, Xavier CB, Demarco FF, Pinheiro ALB, Costa AT, Pozza DH. Comparative chemical study of MTA and Portland cements. *Braz Dent J* 2007; 18:3-7.
8. Asgary S, Eghbal MJ, Parirokh M, Ghoddsi J, Kheirieh S, Brink F. Comparison of mineral trioxide aggregate's composition with Portland cements and a new endodontic cement. *J Endod* 2009; 35:243-250.
9. Bidar M, Moradi S, Jafarzadeh H, Bidad S. Comparative SEM study of the marginal adaptation of white and grey MTA and Portland cement. *Aust Endod J* 2007; 33:2-6.
10. Valera MC, Camargo CHR, Carvalho AS, Gama ERP. In vitro evaluation of apical microleakage using different root-end filling materials. *J Appl Oral Sci* 2006; 14:49-52.
11. Islam I, Chng HK, Yap AU. Comparison of the physical and mechanical properties of MTA and Portland cement. *J Endod*. 2006; 32:193-197.
12. Camilleri J, Montesin FE, Di Silvio L, Pitt Ford TR. The chemical constitution and biocompatibility of accelerated Portland cement for endodontic use. *Int Endod. J*. 2005; 38:834-42.
13. Wucherpfennig AL, Green DB. Mineral trioxide vs. Portland cement – two biocompatible filling materials. *J Endod*. 1999; 25:308.
14. Bodanezi A, Bortoluzzi EA, Munhoz EA, Bernardineli N, Moraes IG, Bramante CM. Radiopacity Portland cement added radiopacifying agents in different proportions. *Rev Inst Ciênc Saúde*. 2009; 27(2):167-70.

15. Holland R, Souza V, Nery MJ, Faraco Júnior IM, Bernabé PFE, Otoboni Filho JA. Reaction of rat connective tissue to implanted dentin tubes filled with mineral trioxide aggregate, Portland cement or calcium hydroxide. *Braz Dent J*. 2001; 12:3-8.
16. Council on Dental Materials and Devices of the New American Dental Association specification Nº 27 for direct filling resins. *J Am Dent Assoc*. 1977; 94(6):1191-4.
17. Council on Dental Materials, Instruments and Equipment of the American Dental Association. The desirability of using radiopaque plastics in dentistry: a status report. *J Am Dent Assoc*. 1981; 102(3):347-9.
18. ANSI/ADA – American Dental Association, “Specification 57: endodontic sealing material, Chicago, ANSI/ADA, 2000.
19. Raitz R, Silva LG, Silva, CL. Comparative study between convencional and digitalized panoramic radiography in the analysis of periapical bone lesions. *Rev Odontol da Universidade Cidade de São Paulo*. 2008; 20(3) 261-6.
20. Gu S, Rasimick BJ, Deutsch AS, Musikant BL. Radiopacity of dental materials using a digital X-ray system. *Dent Mater*. 2006; 22(8):765-70.
21. Akerboom HBM, Kreulen CM, van Amerongen WE, Mol A. Radiopacity os posterior composite resins, composite resin luting cements, and glass ionomer lining cements. *J Prosthet Dent*. 1993; 70(4):351-5.
22. Curtis PM, von Fraunhofer JA, Farman AG. The radiographic density of composite restorative resins. *Oral Surg Oral Med Oral Pathol*. 1990; 70(2):226-30.
23. Ergücü Z, Türkün LS, Onem E, Güneri P. Comparative radiopacity of six flowable resin composites. *Oper Dent*. 2010; 35(4):436-40.
24. Takeshita WM, Castilho JCM, Medici Filho E, Sannomiya EK. An investigation of the density of composite resin using digital radiography. *Braz Dental Science*. 2004; 7(2):6-11.
25. Takeshita, WM, Bissoli CF, Santos LRA, Medici-Filho E, Moraes MEL. Calcium hydroxide cavity liners: a study of the optical density using a digital system. *Rev Odonto Ciência* 2008; 23:63-66.
26. Takeshita, WM, Iwaki LC, Da Silva MC, Iwaki Filho L, Queiroz AD, Geron LB. Comparison of the diagnostic accuracy of direct digital radiography system, filtered images, and subtraction radiography. *Contemporary Clinical Dentistry* 2013; 4(3):338-342.
27. Duda, JG, Losso, EM. The use of mineral trioxide aggregate (MTA) in pediatric dentistry. *Arq. Odontol* 2005; 41(1):93-103.
28. Bodanezi, A, Bortoluzzi, EA, Munhoz, EA, Bernardineli, N, Moraes, IG, Bramante, CM. Radiopacity Portland cement added radiopacifying agents in different proportions .*Rev Inst Ciênc Saúde* 2009; 27(2):167-70.

29. Bissoli, CF, Takeshita, WM, Castilho, JCM, Medici Filho, E, Moraes, MEL. Scan radiology images : a new vision of the future . Dental journal. 2007; 30:34-39.
30. Costa, BC, Campos, CN, Grizzo, LT, Tanomaru, M. Physical and chemical analysis of MTA and Portland cement associated with four different radiopacifiers . Rev Odontol UNESP. 2014; 43(4):228-235.
31. Figueiredo, JAP, Bottesello, BV, Ritter, DD, Cogo, DM, Parlow, IF, Barbisan, AO. Evaluation of Portland cement radiopacity compared to MTA cement. Robrac, 2008; 17 (43) :11-15.
32. Trindade AC, Oliveira EP, Figueiredo M, Poli JA. Comparative analysis of the tissue response to mineral trioxide aggregate (MTA), portland cement and portland cement to radiopaque substance. Journal bras endodontia. 2003; 4(15): 309-314.
33. Song JS, Mante FK, Romanow WJ, Kim S. Chemical analysis of powder and set forms of Portland cement, gray ProRoot MTA, white ProRoot MTA, and gray MTA-Angelus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2006;102(6):809-15. PMid:17138186.



Instructions to the Authors

[Publication Ethics and Publication Malpractice Statement](#) | [Duties of Editor-in-Chief](#) | [Duties of Reviewers](#) | [The Editorial Process](#) | [Clinical trial registry](#) | [Authorship Criteria](#) | [Contribution Details](#) | [Conflicts of Interest/ Competing Interests](#) | [Information For Authors](#) | [Types of Manuscripts and Limits](#) | [Online Submission of Manuscripts](#) | [Preparation of Manuscripts](#) | [Sending a revised manuscript](#) | [Reprints](#) | [Copyrights](#) | [Checklist Manuscript Title Covering letter](#) | [Contributors' form](#)

Publication Ethics and Publication Malpractice Statement



It is necessary to agree upon standards of expected ethical behavior for all parties involved in the act of publishing: the author, the journal editor, the peer reviewer and the publisher. Our ethic statements are based on COPE's Best Practice Guidelines for Journal Editors: <http://publicationethics.org/resources/guidelines>

Duties of Editor-in-Chief



The Editor-in-Chief of the journal is responsible for deciding which of the articles submitted to the journal should be published. The Editor-in-Chief may confer with reviewers in making this decision. He at any time can evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors. The editor and any editorial staff must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers and the publisher, as appropriate. Editor-in-chief should protect the confidentiality of individual information (e.g. that obtained through the dentist-patient relationship). It is almost always necessary to obtain written informed consent from patients described in the case reports and for photographs of the patients. Editor-in-chief should take reasonable responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper, in conjunction with the publisher (or society). Editor-in-Chief should ensure that the advertising, reprint or other commercial revenue has no impact or influence on editorial decisions.

Duties of Reviewers



Reviewers assist the editor in making editorial decisions and may also assist the author in improving the paper, through the editorial communications with the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers. Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views with supporting arguments. Reviewers should identify relevant published work that has not been cited by the authors. Any statement, i.e., an observation, derivation, or argument had been previously reported should be accompanied by the relevant citation. A reviewer should also call to the editor's attention on any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge. Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor and excuse himself from the review process.

The Editorial Process



A manuscript will be reviewed for possible publication with the understanding that it is being submitted to **Contemporary Clinical Dentistry** alone at that point of time and has not been published anywhere, simultaneously submitted, or already accepted for publication elsewhere. The journal expects that authors would authorize one of them to correspond with the Journal for all matters related to the manuscript. All manuscripts received are duly acknowledged. On submission, editors review all submitted manuscripts initially for suitability for formal review. Manuscripts with insufficient originality, serious scientific or technical flaws, or lack of a significant message are rejected before proceeding for formal peer-review. Manuscripts that are unlikely to be of interest to the readers of **Contemporary Clinical Dentistry** are also liable to be rejected at this stage itself.

Manuscripts that are found suitable for publication in **Contemporary Clinical Dentistry** are sent to two or more expert reviewers. During submission, the contributor is requested to provide names of two or three qualified reviewers who have had experience in the subject of the submitted manuscript, but this is not mandatory. The reviewers should not be affiliated with the same institutes as the contributor/s. However, the selection of these reviewers is at the sole discretion of the editor. The journal follows a double-blind review process, wherein the reviewers and authors are unaware of each other's identity. Every manuscript is also assigned to a member of the editorial team, who based on the comments from the reviewers takes a final decision on the manuscript. The comments and suggestions (acceptance/ rejection/ amendments in manuscript) received from reviewers are conveyed to the corresponding author. If required, the author is requested to provide a point by point response to reviewers' comments and submit a revised version of the manuscript. This process is repeated till reviewers and editors are satisfied with the manuscript.

Manuscripts accepted for publication are copy edited for grammar, punctuation, print style, and format. Page proofs are sent to the corresponding author. The corresponding author should be the uploading author and is expected to return the corrected proofs within three days. It may not be possible to incorporate corrections received after that period. The whole process, from submission of the manuscript to final decision and sending and receiving proofs is completed online. To achieve faster and greater dissemination of knowledge and information, the journal publishes articles online as 'Ahead of Print' immediately on acceptance.

Clinical trial registry



Contemporary Clinical Dentistry favors registration of clinical trials and is a signatory to the Statement on publishing clinical trials in Indian biomedical journals. **Contemporary Clinical Dentistry** would publish clinical trials that have been registered with a clinical trial registry that allows free online access to public. Registration in the following trial registers is acceptable: <http://ctri.nic.in/Clinicaltrials/login.php>

Authorship Criteria



Authorship credit should be based only on substantial contributions to each of the three components mentioned below:

1. Concept and design of study or acquisition of data or analysis and interpretation of data;
2. Drafting the article or revising it critically for important intellectual content; and
3. Final approval of the version to be published.

Participation solely in the acquisition of funding or the collection of data does not justify authorship. **General supervision of the research group is not sufficient for authorship.** Each contributor should have participated sufficiently in the work to take public responsibility for appropriate portions of the content of the manuscript. The order of naming the contributors should be based on the relative contribution of the contributor towards the study and writing the manuscript. Once submitted the order cannot be changed without written consent of all the contributors. The journal prescribes a maximum number of authors for manuscripts depending upon the type of manuscript, its scope and number of institutions involved (vide infra). **The authors should provide a justification, if the number of authors exceeds these limits.**

Contribution Details



Contributors should provide a description of contributions made by each of them towards the manuscript. Description should be divided into the following categories, as applicable: concept, design, definition of intellectual content, literature search, clinical studies, experimental studies, data acquisition, data analysis, statistical analysis, manuscript preparation, manuscript editing and manuscript review. Authors' contributions may be printed along

with the article. One or more authors should take responsibility for the integrity of the work as a whole from inception to published article and should be designated as '**guarantor**'. Author should also disclose the source of financial support for the project.

Conflicts of Interest/ Competing Interests



All authors must disclose any and all conflicts of interest they may have with publication of the manuscript or an **institution** or **product** that is mentioned in the manuscript and/or is important to the outcome of the study presented. Authors should also disclose conflict of interest with products that compete with those mentioned in their manuscript.

Information For Authors



Manuscripts must be prepared in accordance with "Uniform requirements for Manuscripts submitted to Biomedical Journal" developed by international committee of medical Journal Editors: <http://www.icmje.org/about-icmje/faqs/icmje-recommendations/>

Journal does not charge for submission, processing or publication of manuscript and even for colour / reproduction of photographs.

Types of Manuscripts and Limits



Original articles: Up to 3000 words excluding references and abstract (max. 250 words) and maximum of 5 pictures and tables.

Case reports: Up to 1000 words excluding references and abstract and up to 10 references and maximum of 3 pictures.

Online Submission of Manuscripts



Articles can also be submitted online from <http://www.contempclindent.org>.

1. First Page File: Prepare the title page, covering letter, acknowledgement, etc. using a word processor program. All information which can reveal your identity should be here. use text/ rtf/doc/PDF files. Do not zip the files.
2. Article file: The main text of the article, beginning from Abstract till References (followed by tables and legends) should be in this file. Do not include any information (such as acknowledgement, your name or institution in page headers, etc.) in this file. Use text/rtf/doc/PDF files. Do not zip the files. Limit the file size to 400 kb. Do not incorporate images in the file. Graphs should be submitted in editable format separately without incorporating them as images in the article file to reduce the size of the file.
3. Images: Submit good quality color images. Each image should be less than 100 kb in size. Size of the image can be reduced by decreasing the actual height and width of the images (keep up to 400 pixels or 3 inches). All image formats (jpeg, tiff, gif, bmp, png, eps etc.) are acceptable; jpeg is most suitable. Resolution should be a minimum of 300dpi for color nad 600dpi for b/w images.
4. Legends: Legends for the figures/images/graphs/tables should be included at the end of the article file.

If the manuscript is submitted online, the contributors' form and copyright transfer form has to be submitted in original with the signatures of all the contributors within two weeks from submission. Hard copies of the images (3 sets), for articles submitted online, should be sent to the journal office at the time of submission of a revised manuscript.

Prof. S. G. Damle,
Editor-In-Chief,
Vice Chancellor's Office,
Maharishi Markandeshwar University,
Mullana (Ambala)-133207., Haryana, INDIA.
Email: journalccd@gmail . com

Preparation of Manuscripts



The text of observational and experimental articles should be divided into sections with the headings: Introduction, Methods, Results, Discussion, References, Tables, Figures, Figure legends, and Acknowledgment. Do not make subheadings in these sections.

Title Page

The title page should carry

1. Type of manuscript (e.g. Original article, Case Report)
2. The title of the article, which should be concise, but informative;
3. Running title or short title not more than 50 characters;
4. The name by which each contributor is known (Last name, First name and initials of middle name), with his or her highest academic degree(s) and institutional affiliation;
5. The name of the department(s) and institution(s) to which the work should be attributed;
6. The name, address, phone numbers, facsimile numbers and e-mail address of the contributor responsible for **uploading and correspondence** about the manuscript;
7. The total number of pages, total number of photographs and word counts separately for abstract and for the text (excluding the references and abstract);
8. Source(s) of support in the form of grants, equipment, drugs, or all of these;
9. Acknowledgement, if any; and
10. If the manuscript was presented as part at a conference/convention/meeting, the organization, place, and exact date on which it was read.

Abstract

Page

The second page should carry the full title of the manuscript and an abstract (of no more than 150 words for case reports or brief reports and 250 words for original articles). The abstract should be structured and state the Context (Background), Aims, Settings and Design, Methods and Material, Statistical analysis used, Results and Conclusions. Below the abstract, authors should provide 3 to 10 keywords.

INTRODUCTION

Introduction should provide/give background of the subject, discuss existing research on the topic, identify the lacunae in the existing literature and explain exactly what the present paper will address, why, and how and summarize the rationale for the study or observation.

Methods

The methods section should include only information that was available at the time, the plan or protocol for the study was written; all information obtained during the conduct of the study belongs in the Results section. Reports of randomized clinical trials should be based on the CONSORT Statement (<http://www.consort-statement.org/>). When reporting experiments on human subjects, indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) and with the Helsinki Declaration of 1975, as revised in 2000 (available at <http://www.wma.net/en/30publications/10policies/b3/>). Accordingly the authors should follow the guidelines related to reporting observational studies (<http://www.strobe-statement.org/>), diagnostic accuracy studies (<http://www.stard-statement.org/>), systematic reviews and meta-analyses (<http://www.prisma-statement.org/>) or in-vitro studies (<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127685/>).

Results

Present your results in logical sequence in the text, tables, and illustrations, giving the main or most important findings first. Do not repeat all the data in the tables or illustrations in the text; emphasize or summarize only important observations. Extra or supplementary materials and technical detail can be placed in an appendix where it will be accessible but will not interrupt the flow of the text; alternatively, it can be published only in the electronic version of the journal.

Discussion

include Summary of key findings (primary outcome measures, secondary outcome measures, results as they relate to a

prior hypothesis); Strengths and limitations of the study (study question, study design, data collection, analysis and interpretation); Interpretation and implications in the context of the totality of evidence (is there a systematic review to refer to, if not, could one be reasonably done here and now?, what this study adds to the available evidence, effects on patient care and health policy, possible mechanisms); Controversies raised by this study; and Future research directions (for this particular research collaboration, underlying mechanisms, clinical research). Do not repeat in detail data or other material given in the Introduction or the Results section.

References

References should be numbered consecutively in the order in which they are first mentioned in the text (not in alphabetic order). Identify references in text, with Arabic numerals in square brackets and superscript, after the punctuation mark (e.g. ^[1]); figures, tables, and graphs by Arabic numerals in square bracket (e.g. [Figure/Table/Graph.10]). Please refer to ICMJE Guidelines(http://www.nlm.nih.gov/bsd/uniform_requirements.html) for more examples.

1. Standard journal article: Nuvvula S, Gaddam KR, Kamatham R. Efficacy of tranexamic acid mouthwash as an alternative for factor replacement in gingival bleeding during dental scaling in cases of hemophilia: A randomized clinical trial. *Contemp Clin Dent* 2014;5:49-53. (If more than SIX authors, list the first **six contributors** followed by *et al.*)
2. Chapter in a book: Mc Donald RE, Avery DR, Dean JA, Jones JE. Local anesthesia and pain control for the child and adolescent. In: Mc Donald and Avery's *Dentistry for the Child and Adolescent*. Dean JA, Avery DR, Mc Donald RE, editors. 9th edition (Restricted South Asia) 2011, Reed Elsevier India Pvt. Ltd: p. 242–3.
3. Reference from URL: American Association of Endodontics. AAE Considerations for regenerative procedures. Available at: http://www.aae.org/uploadedfiles/publications_and_research/research/currentregenerativeendodonticconsiderations.pdf ". Accessed January 23, 2015.

Tables

Tables should be self-explanatory and should not duplicate textual material. Tables with more than 10 columns and 25 rows are not acceptable. Number tables, in Arabic numerals, consecutively in the order of their first citation in the text and supply a brief title/legend for each. Explain in footnotes all the non-standard abbreviations that are used in each table. For footnotes use the following symbols, in this sequence: *, †, ‡, §.

Illustrations (Figures)

Send sharp, glossy, un-mounted, color photographic prints, with height of 4 inches and width of 6 inches. Figures should be numbered consecutively according to the order in which they have been first cited in the text. Each figure should have a label pasted (avoid use of liquid gum for pasting) on its back indicating the number of the figure, the running title, top of the figure and the legends of the figure. Do not write on the back of figures, scratch, or mark them by using paper clips. Print outs of digital photographs are not acceptable. For digital images send TIFF files of minimum 1200x1600 pixel size. Type or print out legends (maximum 40 words, excluding the credit line) for illustrations using double spacing, with Arabic numerals corresponding to the illustrations.

Electronic

Version

Manuscript sent by post must be accompanied by a 3.5 inch (1.44 MB) floppy or CD containing the manuscript.

Sending a revised manuscript



While submitting a revised manuscript, contributors are requested to include, along with single copy of the final revised manuscript, a photocopy of the revised manuscript with the changes underlined in red and copy of the comments with the point to point clarification to each comment. The manuscript number should be written on each of these documents. If the manuscript is submitted online, the contributors' form and copyright transfer form has to be submitted in original with the signatures of all the contributors within two weeks of submission. Hard copies of images should be sent to the office of the journal. **There is no need to send printed manuscript for articles submitted online.**

Reprints



Journal provides no free printed reprints.

Copyrights



The whole of the literary matter in the Contemporary clinical dentistry is copyright and cannot be reproduced without the written permission.

Checklist Manuscript Title Covering letter



Signed by all contributors

Previous publication/ presentations mentioned; Source of funding mentioned; Conflicts of interest disclosed

Authors

Middle name initials to be provided. Author for correspondence should be the uploading author, with e-mail address provided. Number of contributors to be restricted as per the instructions. Identity not revealed in paper except title page (e.g. **name of the institute in Methods, citing previous study as 'our study'**).

Presentation

And

Format

Double spacing. Margins 2.5 cm from all four sides. Title page contains all the desired information. Running title provided (not more than 50 characters). Abstract page contains the full title of the manuscript. Abstract provided. Structured abstract provided for an original article. Key words provided (three or more). Introduction of 75-100 words. Headings in title case (**not ALL CAPITALS or underlined**). References cited in square brackets with superscript. References according to the journal's instructions.

Language and grammar

Uniformly American English. Abbreviations spelt out in full for the first time. Numerals from 1 to 10 spelt out. **Numerals at the beginning of the sentence spelt out.**

Tables and figures

No repetition of data in tables and graphs and in text. Actual numbers from which graphs drawn, provided. Graphs should be in editable format. Figures necessary and of good quality (colour); table and figure numbers in Arabic letters (not Roman). Labels pasted on back of the photographs (no names written); Composite figures are encouraged for case reports, materials and methods etc. to reduce the number of figures. Figure legends provided (not more than 40 words) Patients' privacy maintained, (if not permission taken) Credit note for borrowed figures/tables provided Manuscript provided on a floppy (with single spacing)

Contributors' Form (to be modified as applicable and one signed copy attached with the manuscript)

Contributor's form



Manuscript Title:

Manuscript ID:

I/we certify that I/we have participated sufficiently in contributing to the intellectual content, concept and design of this work or the analysis and interpretation of the data (when applicable), as well as writing of the manuscript, to take public responsibility for it and have agreed to have my/our name listed as a contributor.

I/we believe that the manuscript represents valid work. Neither this manuscript nor one with substantially similar content under my/our authorship has been published or is being considered for publication elsewhere, except as described in the covering letter. I/we certify that all the data collected during the study is presented in this manuscript and no data from the study has been or will be published separately. I/we attest that, if requested by the editors, I/we will provide the data/information or will cooperate fully in obtaining and providing the data/information on which the manuscript is based, for examination by the editors or their assignees. Financial interests, direct or indirect, that exist or may be perceived to exist for individual contributors in connection with the content of this paper have been disclosed in the cover letter. Sources of outside support of the project are named in the covering letter.

I/We hereby transfer, assign, or otherwise convey all copyright ownership, including any and all rights incidental thereto, exclusively to the Journal, Contemporary Clinical Dentistry (CCD), in the event that such work is published by the

Contemporary Clinical Dentistry (CCD). The Journal, Contemporary Clinical Dentistry (CCD) shall own the work, including

1. copyright;
2. the right to grant permission to republish the article in whole or in part, with or without fee;
3. the right to produce preprints or reprints and translate into languages other than English for sale or free distribution; and
4. the right to republish the work in a collection of articles in any other mechanical or electronic format.

We give the rights to the corresponding author to make necessary changes as per the request of the journal, do the rest of the correspondence on our behalf and he/she will act as the guarantor for the manuscript on our behalf.

All persons who have made substantial contributions to the work reported in the manuscript, but who are not contributors, are named in the Acknowledgment and have given me/us their written permission to be named. If I/we do not include an Acknowledgment that means I/we have not received substantial contributions from non-contributors and no contributor has been omitted.

	Name	Signature	Date
signed			
1	-----	-----	-----
2	-----	-----	-----
3	-----	-----	-----
4	-----	-----	-----
5	-----	-----	-----
6	-----	-----	-----

(up to 4 contributors for case report/ images/ review and up to 6 contributors for original studies)